Wedbush Has Positive Outlook for Arvinas Q1 Earnings

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Analysts at Wedbush lifted their Q1 2025 earnings per share estimates for Arvinas in a research report issued to clients and investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.76) per share for the quarter, up from their prior estimate of ($0.93). Wedbush currently has a "Neutral" rating and a $12.00 target price on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas' Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter in the previous year, the business earned ($2.53) EPS.

A number of other analysts have also weighed in on the company. Oppenheimer lowered Arvinas from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 11th. Guggenheim lowered their target price on Arvinas from $57.00 to $32.00 and set a "buy" rating for the company in a report on Thursday, March 13th. BTIG Research assumed coverage on Arvinas in a report on Tuesday, December 10th. They set a "buy" rating and a $69.00 target price for the company. Barclays lowered their target price on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Finally, BMO Capital Markets set a $20.00 target price on Arvinas and gave the stock an "outperform" rating in a report on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Arvinas currently has an average rating of "Moderate Buy" and a consensus target price of $37.47.

Remove Ads

Arvinas Trading Up 4.9 %

Shares of NASDAQ ARVN traded up $0.43 during trading hours on Monday, reaching $9.13. The stock had a trading volume of 1,309,064 shares, compared to its average volume of 923,802. The firm has a market cap of $627.89 million, a price-to-earnings ratio of -3.30 and a beta of 1.95. The business's fifty day moving average price is $16.65 and its two-hundred day moving average price is $21.50. Arvinas has a 52-week low of $7.91 and a 52-week high of $44.85.

Institutional Investors Weigh In On Arvinas

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARVN. T. Rowe Price Investment Management Inc. acquired a new stake in Arvinas during the 4th quarter worth about $42,332,000. Norges Bank acquired a new stake in Arvinas during the 4th quarter worth about $23,845,000. Boxer Capital Management LLC acquired a new stake in Arvinas during the 4th quarter worth about $20,294,000. Braidwell LP grew its position in Arvinas by 148.3% during the 3rd quarter. Braidwell LP now owns 1,284,472 shares of the company's stock worth $31,637,000 after purchasing an additional 767,242 shares during the period. Finally, RTW Investments LP grew its position in Arvinas by 19.8% during the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares during the period. 95.19% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Arvinas

In related news, CEO John G. Houston sold 31,338 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. This represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ian Taylor sold 9,020 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total value of $150,724.20. Following the completion of the transaction, the insider now directly owns 159,121 shares in the company, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 in the last ninety days. Company insiders own 5.23% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.